The science of USP 1 and 2 dissolution: Present challenges and future relevance

Pharmaceutical Research

Volumn 26, Issue 6, 2009, Pages 1289-1302

  Gray, Vivian ^a   Kelly, Gregg ^b   Xia, Min ^c   Butler, Chris ^d   Thomas, Saji ^e   Mayock, Stephen ^f  

^a V A GRAY CONSULTING INC   (United States)

^b PFIZER INC   (United States)

^c VERTEX PHARMACEUTICALS   (United States)

^d Validation and CAPA   (United States)

^e QC Lab Operations   (United States)

^f CATALENT PHARMA SOLUTIONS   (United States)

Author keywords

Biorelevant methods; Dissolution; In vitro in vivo correlation; Quality by design; Variability

Indexed keywords

APPARATUS; CALIBRATOR; CORRELATION ANALYSIS; DISSOLUTION; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SCREENING; HYDRODYNAMICS; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW;

CALIBRATION; CHEMISTRY, PHARMACEUTICAL; QUALITY CONTROL; SOLUBILITY; TABLETS; UNITED STATES;

EID: 65549101635     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9822-x     Document Type: Review

References (135)

1. United States Pharmacopeia and National Formulary USP 29-NF 24. The United States Pharmacopeial Convention, Inc., Rockville, MD, 2007.
2. A. S. Hussain. Quality by design and risk based regulatory scrutiny: connecting the dots. Presentation at AAPS 39th Annual Pharmaceutical Technologies Conference at Arden House, Harriman, NY, Jan. 25-30 (2004).
3. L. Buhse. Measuring and Managing Method Variability. CDER Advisory Committee for Pharmaceutical Science, October 25, 2005, Rockville, MD, 1:184-219 (2005).
4. S. A. Qureshi 2004 A new crescent-shaped spindle for drug dissolution testing-but why a new spindle? Dissolution Technol. 11 13 18
5. F. J. Muzzio and P. Armenante. Action plan for the development of scientifically based bioavailability and dissolution testing systems. Presented at Drug Dissolution and Release Research Program Meeting, Nov. 17, 2005, Piscataway, NJ (Rutgers Univ.), pp. 1-10.
6. W. Swichtenberg. Dissolution Testing in the 21st Century, Hot Topic minutes. AAPS National Meeting, San Antonio, TX, Nov.1, 2006. Comments attributed to Ajaz Hussain. http://www.pharmamanufacturing.com/articles/2006/ 213.html (accessed 11/25/2008).
7. H. Zhang L. Yu 2004 Dissolution testing for solid oral drug products: Theoretical considerations J. Am. Pharm. Rev. 7 26 31 (Pubitemid 39468088)
8. J. Woodcock 2004 The concept of pharmaceutical quality J. Am. Pharm. Rev. 7 10 15
9. J. M. Clarke L. E. Ramsay J. R. Shelton M. J. Tidd S. Murray R. F. Palmer 1977 Factors influencing comparative bioavailability y of spironolactone tablets J. Pharm. Sci. 66 1429 1432 (Pubitemid 8184943)
10. P. Gao B. D. Rush W. P. Pfund T. Huang J. M. Baauer W. Morozowich M. S. Kuo M. J. Hageman 2003 Development of a supersaturatable SEDDS (S-SEDDS) formulation of Paclitaxel with improved oral bioavailability J. Pharm. Sci. 92 2386 2398 (Pubitemid 37484765)
11. J. Kukura J. L. Baxter F. J. Muzzio 2004 Shear distribution and variability in the USP Apparatus 2 turbulent conditions Intl. J. Pharm. 279 9 17 (Pubitemid 38968637)
12. A. M. Healy L. G. McCarthy K. M. Gallagher O. I. Corrigan 2002 Sensitivity of dissolution rate to location in the paddle dissolution apparatus J. Pharm. Pharmacol. 54 441 444 (Pubitemid 34232346)
13. L. Buhse. Dissolution apparatus qualification. Presentation at Challenges for Dissolution Testing for the 21st Century, May 3, 2006, Arlington, VA.
14. B. Crist D. Spisak 2005 evaluation of the induced variance of physical parameters on the calibrated USP dissolution apparatus 1 and 2 Dissolution Technol. 12 28 31
15. P. Scott 2005 Geometric irregularities common to the dissolution vessel Dissolution Technol. 12 18 21
16. J. Burmicz 2005 Observations of systemic errors in calibrator tablet testing Dissolution Technol. 12 33 34
17. T. Foster W. Brown 2005 USP dissolution calibrators: Re-examination and appraisal Dissolution Technol. 12 6 8
18. A. S. Achanta V. A. Gray T. L. Cecil L. T. Grady 1995 Evaluation of the performance of prednisone and salicylic acid USP dissolution calibrators Drug Dev. Ind. Pharm. 21 1171 1182
19. V. Gray M. Barot P. Bhattacharyya J. Burmicz B. Crist T. Foster R. Hanson H. Lam L. Leeson J. Mauger T. Moore W. Mueller M. Oates J. L. Raton W. Brown 2005 Activities of the USP Project Team on dissolution calibration Dissolution Technol. 12 35 36
20. T. Mirza Y. Joshi Q. Liu R. Vivilecchia 2005 Evaluation of dissolution hydrodynamics in the USP, Peak™ and flat-bottom vessels using different solubility drugs Dissolution Technol. 12 11 16
21. J. B. Dressman G. L. Amidon C. Reppas V. P. Shah 1998 Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms Pharm. Res. 15 11 22 (Pubitemid 28080861)
22. K. Khan D. Rooke 1976 Effect of disintegrant type upon the relationship between compressional pressure and dissolution efficiency J. Pharm. Pharmacol. 28 633 636
23. G. Levy J. M. Antkowiak J. A. Procknall D. C. White 1963 J. Pharm. Sci. 52 1047 1051
24. Z. Chowhan L. Palagyi 1978 Hardness increase induced by partial moisture loss in compressed tablets and its effect on in vitro dissolution J. Pharm. Sci. 67 1385 1389 (Pubitemid 9031058)
25. C. Urdinola V. Gray L. Grady 1981 Effects of packaging and storage on the dissolution of model prednisone tablets Am. J. Hosp. Pharm. 38 1322 1327 (Pubitemid 12245063)
26. Z. Chowhan L. Chi 1986 Drug-excipient interactions resulting from powder mixing IV: Role of lubricants and their effect on in vitro dissolution J. Pharm. Sci. 75 542 545 (Pubitemid 16098034)
27. H. Sunada I. Shinohara A. Otsuka Y. Yonezawa 1989 Changes of surface area in the dissolution process of crystalline substances. II. Dissolution and simulation curves for mixed systems of sieved particles Chem. Pharm. Bull. 37 467 470 (Pubitemid 19082592)
28. Z. Chowhan 1994 Factors affecting dissolution of drugs and their stability upon aging in solid dosage forms Pharm. Technol. 18 60 73
29. J. Babu J. Pandit 1999 Effect of aging on the dissolution stability of glibenclamide b-cyclodextrin complex Drug Dev. Ind. Pharm. 25 1215 1219
30. M. Bartolomei P. Bertocchi M. C. Ramusino N. Santucci L. Valvo 1999 Physico-chemical characterization of the modifications I and II of (R, S) propranolol hydrochloride: Solubility and dissolution studies J. Pharm. Biomed. Anal. 21 299 309 (Pubitemid 29502566)
31. N. Sarisuta T. Thamsakdakorn S. Jateleela 1999 Effects of temperature and humidity on the physical properties of piroxicam tablets Pharm. Technol. 23 66 80 (Pubitemid 29185688)
32. B. Rohrs T. Thamann P. Gao D. Stelzer M. Bergren R. Chao 1999 Tablet dissolution affected by a moisture mediated solid-state interaction between drug and disintegrant Pharm. Res. 16 1850 1856 (Pubitemid 30040701)
33. S. Spireas T. Wang R. Grover 1999 Effects of Powder substrate on the dissolution properties of methyclothiazide liquisolid compacts Drug Dev. Ind. Pharm. 25 163 168 (Pubitemid 29072777)
34. A. Adebayo O. Itiola 2003 Effects of breadfruit and cocoyam starch mucilage binders on disintegration and dissolution behaviors of paracetamol tablet formulations Pharm. Technol. 25 78 90 (Pubitemid 37101919)
35. J. Nerurkar H. Jun J. Price M. Park 2005 Controlled-release matrix tablets of ibuprofen using cellulose ethers and carrageenans: Effect of formulation factors on dissolution rates Eur. J. Pharm. Biopharm. 61 56 68 (Pubitemid 41096689)
36. H. Kranz T. Wagner 2006 Effects of formulation and process variables on the release of a weakly basic drug from single unit extended release formulations Eur. J. Pharm. Biopharm. 62 70 76 (Pubitemid 41736027)
37. S. Furlanetto M. Cirri F. Maestrelli G. Corti P. Mura 2006 Study of formulation variables influencing the drug release rate from matrix tablets by experimental design Eur. J. Pharm. Biopharm. 62 77 84 (Pubitemid 41736028)
38. D. G. Alvarez 2006 Comparison of acrylic and cellulose-based matrix formers for sustained drug release Drug Deliv. Technol. 6 61 65
39. A. Dokoumetzidis P. Macheras 2006 A century of dissolution research: From Noyes and Whitney to the Biopharmaceutics Classification System Int. J. Pharm. 321 1 11 (Pubitemid 44247428)
40. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Dissolution testing of immediate release dosage forms: Guidance for industry. US Government Printing Office, Rockville, MD, 1997.
41. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Q1A(R2) stability testing of new drug substances and products: Guidance for industry. US Government Printing Office, Rockville, MD, 2003.
42. M. A. Khan A. A. Karnachi V. Agarwal S. R. Vaithiyalingam S. Nazzal I. K. Reddy 2000 Stability characterization of controlled release coprecipitates and solid dispersions J. Control. Release 63 1 6 (Pubitemid 30046937)
43. S. Fitzpatrick J. F. McCabe C. R. Petts S. W. Booth 2002 Effect of moisture on polyvinylpyrrolidone in accelerated stability testing Int. J. Pharm. 246 143 151 (Pubitemid 35247987)
44. N. V. Phadnis R. Suryanarayanan 1997 Polymorphism in anhydrous theophylline-Implications on the dissolution rate of theophylline tablets J. Pharm. Sci. 86 1256 1263 (Pubitemid 27486097)
45. H. Marchais G. Cayzeele J. Y. Legendre M. Skiba P. Arnaud 2003 Cross-linking of hard gelatin carbamazepine capsules: Effect of dissolution conditions on in vitro drug release Eur. J. Pharm. Sci. 19 129 132 (Pubitemid 36668039)
46. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. SUPAC-IR: Immediate-release solid oral dosage forms: Scale-up and post-approval changes: Chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation: Guidance for industry. US Government Printing Office, Rockville, MD, 1995.
47. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. SUPAC-MR: Modified release solid oral dosage forms: Scale-up and post-approval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing and in vivo bioequivalence documentation: Guidance for industry. US Government Printing Office, Rockville, MD, 1997.
48. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system: Guidance for industry. US Government Printing Office, Rockville, MD, 2000.
49. International Conference on Harmonization. Guidance on Q6A specifications: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances, Federal Register 65(251), 83041-83063 (2000).
50. T. O'Hara A. Dunne J. Butler J. Devane 1998 A review of methods used to compare dissolution profile data Pharm. Sci. Technol. Today 1 214 223 (Pubitemid 28387122)
51. J. W. Moore H. H. Flanner 1996 Mathematical comparison of dissolution profiles Pharm. Technol. 20 64 74 (Pubitemid 126450495)
52. 2 Pharm. Res. 15 6 889 896 (Pubitemid 28307831)
53. M. Ma R. Lin J. Liu 1999 Statistical evaluations of dissolution similarity Stat. Sin. 9 1011 1027
54. P. Costa 2001 An alternative method to the evaluation of similarity factor in dissolution testing Int. J. Pharm. 220 77 83 (Pubitemid 32476843)
55. M. Vertzoni M. Symillides A. Iliadis E. Nicolaides C. Reppas 2003 Comparison of simulated cumulative drug versus time data sets with indices Eur. J. Pharm. Biopharm. 56 421 428 (Pubitemid 37351030)
56. P. Sathe Y. Tsong V. P. Shah 1996 In vitro dissolution profile comparison-Statistics and analysis, model dependent approach Pharm. Res. 13 2 1799 1803 (Pubitemid 27034110)
57. J. E. Polli S. Rekhi V. P. Shah 1996 Methods to compare dissolution profiles Drug. Info. J. 30 1113 1120 (Pubitemid 26384608)
58. Y. Tsong T. Hammerstrom J. Chen 1997 Multipoint dissolution specification and acceptance sampling rule based on profile modeling and principal component analysis J. Biopharm. Stat. 7 3 423 439 (Pubitemid 27326809)
59. H. J. Ju S.-J. Liaw 1997 On the assessment of similarity of drug dissolution profiles-A simulation study Drug Info. J. 31 1273 1289 (Pubitemid 27509632)
60. 2 statistic. Pharm. Technol. February, pp. 46-54 (2001).
61. H. Saranadasa K. Krishnamoorthy 2005 A multivariate test for similarity of two dissolution profiles J. Biopharm. Stat. 15 256 278 (Pubitemid 40404350)
62. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations: Guidance for industry. US Government Printing Office, Rockville, MD, 1997.
63. G. L. Amidon H. L. Lennernas V. P. Shah J. R. Crison 1995 A theoretical basis for a biopharmaceutical drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 413 420
64. L. X. Yu G. L. Amidon J. E. Polli H. Zhao M. U. Mehta D. P. Conner V. P. Shah L. J. Lesko M. L. Chen V. H. L. Lee A. S. Hussain 2002 Biopharmaceutics classification system: The scientific basis for biowaiver extensions Pharm. Res. 19 921 925
65. J. E. Polli G. S. Rekhi L. L. Augsburger V. P. Shah 1997 Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets J. Pharm. Sci. 86 690 700 (Pubitemid 27248819)
66. E. Rinaki A. Dokoumetzidis G. Valsami P. Macheras 2004 Identification of biowaivers among class II drugs: Theoretical justification and practical examples Pharm. Res. 21 1567 1572 (Pubitemid 41184386)
67. USP Subcommittee on Biopharmaceutics 1988 In vitro/in vivo correlation for extended-release oral dosage forms Pharm. Forum 14 4 4160 4161
68. J. L. Cohen B. B. Hubert L. J. Leeson C. T. Rhodes J. R. Robinson T. J. Roseman E. Shefter 1990 The development of USP dissolution and drug release standards Pharm. Res. 7 983 987 (Pubitemid 20366722)
69. Pharmacopeial Forum. In vitro and in vivo evaluation of dosage forms. Pharm. Forum. 19(3):5366-5379 (1993).
70. J. P. Skelly G. L. Amidon W. H. Barr L. Z. Benet J. E. Carter J. R. Robinson V. P. Shah A. Yacobi 1990 Report of Workshop on In vitro and In Vivo Testing and Correlation for Oral Controlled/Modified Release Dosage Forms J. Pharm. Sci. 79 849 854 (Pubitemid 20309002)
71. United States Pharmacopeia and National Formulary USP 23-NF 18. The United States Pharmacopeial Convention, Inc., Rockville, MD, 1994.
72. J. Emami. In vitro-In vivo correlation: From theory to applications. J. Pharm. Pharmaceut. Sci. 9:169-189 (2006). http://www.ualberta.ca/~csps/JPPS9-2/ Jaber-Emami/MS-190.htm (accessed 11/25/2008).
73. W. R. Gillespie. Convolution-based approaches for in vitro-in vivo correlation modeling. In D. Young, J. Devane, and J. Butler (eds.), In Vitro In Vivo Correlations, Vol. 423, Plenum, New York, 1997, pp. 53-65. (Pubitemid 27347192)
74. J.-M. Cardot E. Beyssac 1993 In vitro/in vivo correlations: Scientific implications and standardization Eur. J. Drug Metab. Pharmacokinet. 18 113 120 (Pubitemid 23177464)
75. N. Sirisuth N. D. Eddington 2002 In vitro-in vivo correlation, definitions and regulatory guidance Int. J. Generic Drugs. Part 2 1 11
76. D. Young, J. G. Devane, and J. Butler (Eds.), In Vitro In Vivo Correlations, Vol. 423, Plenum, New York, 1997.
77. K. Yamaoka T. Nakagawa T. Uno 1978 Statistical moments in pharmacokinetics J. Pharmacokinet. Biopharm. 6 547 558
78. J. Drewe P. Guitard 1993 In vitro-in vivo correlation for modified-release formulations J. Pharm. Sci. 82 2 132 137 (Pubitemid 23147738)
79. In vitro and in vivo evaluations of dosage forms <1088>. In United States Pharmacopeia and National Formulary USP 30-NF 25. The United States Pharmacopeial Convention, Inc., Rockville, MD,.2008.
80. M. M. Akbor R. Sultana A. Ullah M. A. K. Azad A. M. Latif A. Hasnat 2007 In vitro in vivo correlation (IVIVC) of immediate release (IR) J. Pharm. Sci. 6 2 113 119
81. E. Jantratid S. Prakongpan G. L. Amidon J. B. Dressman 2006 Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products cimetidine Clin. Pharmacokinet. 45 4 385 399
82. N. Sirisuth L. L. Augsburger N. D. Eddington 2002 Development and validation of a non-linear IVIVC model for a diltiazem extended release formulation Biopharm. Drug Disp. 23 1 8 (Pubitemid 34256937)
83. S. Takka A. Sakr A. Goldberg 2003 Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets J. Control. Release 88 147 157 (Pubitemid 36173960)
84. D. Sandeep Y. H. Qiu S. Emil G. L. Cao G. G. Richard 2005 Once-a-day extended-release dosage form of divalproex sodium III: Development and validation of a level A in vitro-in vivo correlation (IVIVC) J. Pharm Sci. 94 9 1949 1956 (Pubitemid 41551479)
85. G. Balan P. Timmins D. S. Greene P. H. Marathe 2001 In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers J. Pharm. Sci. 90 8 1176 1185 (Pubitemid 32776999)
86. B.-M. Lue F. S. Nielsen T. Magnussen H. M. Schou K. Kristensen L. Jacobsen A. Mullertz 2008 Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorly soluble model compound Eur. J. Pharm. Biopharm. 69 2 648 657
87. P. Buch, P. Langguth, M. Kataoka, S. Yamashita. IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system. J. Pharm. Sci. Published online in Wiley InterScience ( www.interscience.wiley. com ). doi: 10.1002/jps.21576 .
88. J.-M. Cardot E. Beyssac M. Alric 2007 In vitro-in vivo correlation: Importance of dissolution in IVIVC Dissolution Technol. 14 1 15 19 (Pubitemid 46364478)
89. S. F. Li, A. E. Royce, and A.T. M. Serajuddin. In vitro-in vivo correlation in dosage form development: Case studies book biopharmaceutics applications in drug development. Springer, US, pp. 359-382. ISBN 978-0-387-72378-5 (print), 978-0-387-72379-2 (online).
90. P. Veng-Pedersen J. V. S. Gobburu M. C. Meyer A. B. Straughn 2000 Carbamazepine level A in vivo-in vitro correlation (IVIVC): A scaled convolution based predictive approach Biopharm. Drug Dispos. 21 1 1 6
91. H. Potthast J. B. Dressman H. E. Junginger K. K. Midha H. Oeser V. P. Shah 2005 Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen J. Pharm. Sci. 94 10 2121 2131 (Pubitemid 41670501)
92. D. Young D. Chilukuri R. Becker S. Bigora C. Farrell T. Shepard 2002 Approaches to developing a level-A IVIVC for injectable dosage forms AAPS PharmSci. 4 4 M1357
93. N. Chidambaram D. J.. Burgess 1999 A novel in vitro release method for submicron-sized dispersed system AAPS PharmSci. 1 3 32 40
94. J. E. Polli 2000 IVIVR versus IVIVC Dissolution Technol. 7 3 6 9
95. J. E. Polli M. J. Ginski 1998 Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities Pharm. Res. 15 47 52 (Pubitemid 28080865)
96. T. Zoeller S. Klein 2007 Simplified biorelevant media for screening dissolution performance of poorly soluble drugs Dissolution Technol. 14 8 13
97. Q. Wang, and V. Gray. HPLC in Dissolution Testing. In S. Ahuja, and M. Dong (eds.), Handbook of Pharmaceutical Analysis by HPLC, Vol. 6 (Separation Science and Technology), Elsevier Academic, London, UK, 2005.
98. R. Hanson S. Vangani A. Salt J. Burmicz S. Thomas J. Seely J. Kraemer J. Kretz B. Crist 2007 Commentaries on mechanical versus chemical calibration Dissolution Technol. 14 2 6 18
99. O. S. Degenhardt B. Waters A. Rebelo-Cameiro A. Meyer H. Brunner N. P. Toltl 2004 Comparison of the effectiveness of various deaeration techniques Dissolution Technol. 11 1 6 11
100. S. Vangani T. Flick G. Tamayo R. Chiu N. Cauchon 2007 Vibration measurements on dissolution systems and effects on dissolution of predisone tablets RS Dissolution Technol. 14 1 6 14
101. M. Tanaka H. Fujiwara M. Fujiwara 2005 Effect of the irregular inner shape of a glass vessel on prednisone dissolution results Dissolution Technol. 12 4 15 19
102. J. Eaton G. Deng W. W. Hauck W. E. Brown R. G. Manning S. Wahab 2007 Perturbation study of dissolution apparatus variables-A design of experiment approach Dissolution Technol. 14 20 26
103. N. Kaniwa 2002 Typical variability in dissolution testing and its qualification Pharm. Tech. Jpn. 18 105 111
104. S. A. Qureshi I. J. McGilveray 1999 Typical variability in drug dissolution testing: study USP and FDA calibrator tablets and a marketed drug (glibenclamide) product Eur. J. Pharm. Sci. 7 249 258 (Pubitemid 29015743)
105. D. C. Cox C. E. Wells W. B. Furnam T. S. Savage A. C. King 1982 Systematic error associated with apparatus 2 of the USP dissolution test. USBN 0-12-088547-6II: Effects of deviations in vessel curvature from that of a sphere J. Pharm. Sci. 71 395 399
106. Y. Wu D. O. Kildsig E. S. Ghaly 2004 Effect of hydrodynamic environment on tablets dissolution rate Pharm. Dev. Technol. 9 25 37 (Pubitemid 38250224)
107. J. L. Baxter J. Kukura F. J. Muzzio 2006 Shear-induced variability in the United States Pharmacopeia Apparatus 2: Modifications to the existing system AAPS J. 7 4 E857 E864
108. D. D'Arcy 2005 Evaluation of hydrodynamics in the basket dissolution apparatus using computational fluid dynamics-Dissolution rate implications Eur. J. Pharm. Sci. 27 2-3 259 267
109. L. G. McCarthy, G. Bradley, J. C. Sexton, O. I. Corrigan, and A. M. Healy. Computational fluid dynamics modeling of the paddle dissolution apparatus: Agitation rate, mixing patterns, and fluid velocities. AAPS PharmSciTech. 5(2):Article 31 (2004).
110. L. G. McCarthy, C. Kosiol, A. M. Healy, G. Bradley, J. C. Sexton, and O. I. Corrigan. Simulating the hydrodynamic conditions in the United States Pharmacopeia paddle dissolution apparatus. AAPS PharmSciTech. 4(2):Article 22 (2003).
111. R. A. Soltero J. M. Hoover T. F. Jones M. Standish 1989 Effects of sinker shapes on dissolution profiles J. Pharm. Sci. 78 35 39 (Pubitemid 19079808)
112. S. A. Qureshi J. Shabnam 2001 Cause of high variability in drug dissolution testing and its impact on setting tolerances Eur. J. Pharm. Sci. 12 271 276
113. S. Diebold. Hydrodynamics and dissolution-Influence of hydrodynamics on dissolution rate of poorly soluble drugs. PhD Dissertation, University of Frankfurt, Shaker Verlag, Aachen, Germany.
114. C. Collins R. Nair 1998 Comparative evaluation of mixing dynamics in USP Apparatus 2 using standard USP vessels and PEAK™ vessels Dissolution Technol. 5 2 17 21
115. A. H. Beckett, T. T. Quach, and G. S. Kurs. Improved hydrodynamics for USP Apparatus 2. Dissolution Technol. 3:7-10, 18 (1996).
116. S. A. Qureshi 2006 Comparative impact of stirring and shearing in drug dissolution testing with USP paddle and crescent-shaped spindles Dissolution Technol. 13 25 30
117. M. S. F. Ross M. Rasis 1998 Mega paddle-A recommendation to modify Apparatus 2 used in the USP general test for dissolution <711> Pharm. Forum 24 214 (Pubitemid 128788805)
118. A. S. Hussain. Drug Release Specification: In Vivo Relevance. FDA Advisory Committee for Pharmaceutical Sciences, October 25, 2005.
119. M. A. Staples. The concept of quality by design. AAPS Workshop on Pharmaceutical Stability Testing to Support Global Markets, Sept. 10, 2007.
120. M. M. Nasr. Quality by design and its relevance to dissolution. AAPS Workshop on Challenges for Dissolution Testing for the 21st Century, Arlington, VA, May 1, 2006.
121. S. Furlanetto F. Maestrelli S. Orlandini S. Pinzauti P. Mura 2003 Optimization of dissolution test precision for a ketoprofen oral extended-release product J. Pharm. Biomed. Anal. 32 159 165 (Pubitemid 36403609)
122. C. Graffner M. Sarkela K. Gjellan G. Nork 1996 Use of statistical experimental design in the further development of a discriminating in vitro release test for ethyl cellulose ER-coated spheres of remoxipride Eur. J. Pharm. Sci. 4 73 83 (Pubitemid 26096222)
123. C. Sanchez-Lafuente S. Furlanetto M. Fernandez-Arevalo J. Alvarez-Fuentes A. M. Rabasco M. T. Faucci S. Pinzauti P. Mura 2002 Didanosine extended-release matrix tablets: Optimization of formulation variables using statistical experimental design Int. J. Pharm. 237 107 118 (Pubitemid 34310484)
124. M. A. Khan S. V. Sastry S. R. Vaithiyalingam V. Agarwal S. Nazzal I. K. Reddy 2000 Captopril gastrointestinal therapeutic system coated with cellulose acetate pseudolatex: Evaluation of main effects of several formulation variables Int. J. Pharm. 193 147 156 (Pubitemid 30001857)
125. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. PAT-A framework for innovative pharmaceutical development, manufacturing, and quality assurance: Guidance for industry. US Government Printing Office, Rockville, MD, 2007.
126. J. D. Kirsch J. K. Drennen 1995 Determination of film-coated tablet parameters by near-infrared spectroscopy J. Pharm. Biomed. Anal. 13 1273 1281
127. M. P. Freitas A. Sabadin L. M. Silva F. M. Giannotti D. A. do Couto E. Tonhi R. S. Medeiros G. L. Coco V. F. T. Russo J. A. Martins 2005 Prediction of drug dissolution profiles from tablets using NIR diffuse reflectance spectroscopy: A rapid and nondestructive method J. Pharm. Biomed. Anal. 39 17 21 (Pubitemid 41112113)
128. M. Blanco M. Alcalá J. M. González E. Torras 2007 A process analytical technology approach based on near infrared spectroscopy: Tablet hardness, content uniformity, and dissolution test measurements of intact tablets J. Pharm. Sci. 95 2137 2144 (Pubitemid 44568525)
129. J. A. Spencer Z. Gao T. Moore L. F. Buhse P. F. Taday D. A. Newnham Y. Shen A. Portieri A. S. Hussain 2008 Delayed release tablet dissolution related to coating thickness by terahertz pulsed image mapping J. Pharm. Sci. 97 1543 1550
130. A. S. Hussain. Biopharmaceutics and drug product quality: Performance tests for drug products, a look into the future. USP Annual Scientific Meeting: The Science of Quality, Iselin, NJ, Sept. 26, 2004.
131. A. S. Hussain. Achieving and demonstrating "quality-by-design" with respect to drug release/dissolution performance for conventional or immediate release solid oral dosage forms. FDA Advisory Committee for Pharmaceutical Sciences meeting, October 25, 2005.
132. The dissolution procedure: Development and validation <1092>. In The United States Pharmacopeia USP 30, United States Pharmacopeial Convention, Inc., Rockville, MD, 2007.
133. L. D. Torbeck 1996 Assay validation: Ruggedness and robustness with designed experiments Pharm:Technol. 20 169 172
134. P. A. Peters T. C. Paino 1999 Robustness testing of an HPLC method using experimental design Pharm. Technol., Anal. Valid. Suppl. 23 8 14
135. W. J. Youden, and E. H. Steine. Statistical manual of the association of official analytical chemists. AOAC International, Arlington, VA, 1975.